Swiss National Bank’s Monte Rosa Therapeutics GLUE Stock Holding History

Swiss National Bank’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01M	Buy	+61,100	New	+$1.17M	﹤0.01%	2155
2023 Q4	–	Sell	-91,300	Closed	-$437K	–	2569
2023 Q3	$437K	Hold	91,300	–	–	﹤0.01%	2534
2023 Q2	$625K	Buy	91,300 +49,500	+118%	+$320K	﹤0.01%	2496
2023 Q1	$326K	Sell	41,800 -2,100	-5%	-$14.6K	﹤0.01%	2597
2022 Q4	$334K	Hold	43,900	–	–	﹤0.01%	2640
2022 Q3	$359K	Hold	43,900	–	–	﹤0.01%	2646
2022 Q2	$425K	Buy	43,900 +16,400	+60%	+$165K	﹤0.01%	2651
2022 Q1	$386K	Buy	27,500 +1,900	+7%	+$26.4K	﹤0.01%	2633
2021 Q4	$523K	Buy	+25,600	New	+$536K	﹤0.01%	2651

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Swiss National Bank's GLUE Position: Q1 2026 in Review

Swiss National Bank opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 61,100 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #2155 among its holdings. This is a return to the name: Swiss National Bank previously reported a position in GLUE as recently as Q3 2023.

Swiss National Bank first reported a position in GLUE in Q4 2021 and has held it in 9 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

Swiss National Bank held 61,100 shares of Monte Rosa Therapeutics worth $1.01M as of Q1 2026.
Monte Rosa Therapeutics was a new Swiss National Bank position in Q1 2026.
Monte Rosa Therapeutics made up ﹤0.01% of Swiss National Bank's portfolio in Q1 2026, its #2155 holding.
Swiss National Bank first reported a position in Monte Rosa Therapeutics in Q4 2021 and has held it in 9 quarters since.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.